Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer vaccines: Material breach.

Literature DB >> 24352360

Cancer vaccines: Material breach.

Elie Dolgin.

Abstract

Entities: Disease

Mesh：

Substances：
Cancer Vaccines

Year: 2013 PMID： 24352360 DOI： 10.1038/504S16a

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

7 in total

1. In situ regulation of DC subsets and T cells mediates tumor regression in mice.

Authors: Omar A Ali; Dwaine Emerich; Glenn Dranoff; David J Mooney
Journal: Sci Transl Med Date: 2009-11-25 Impact factor: 17.956

2. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.

Authors: Ankur Singh; Hong Qin; Irina Fernandez; Jinsong Wei; Jian Lin; Larry W Kwak; Krishnendu Roy
Journal: J Control Release Date: 2011-06-21 Impact factor: 9.776

3. Biomaterial-based vaccine induces regression of established intracranial glioma in rats.

Authors: Omar A Ali; Ed Doherty; William J Bell; Tracie Fradet; Jebecka Hudak; Marie-Therese Laliberte; David J Mooney; Dwaine F Emerich
Journal: Pharm Res Date: 2011-01-12 Impact factor: 4.200

4. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

Authors: Brandon Kwong; S Annie Gai; Jamal Elkhader; K Dane Wittrup; Darrell J Irvine
Journal: Cancer Res Date: 2013-02-22 Impact factor: 12.701

5. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.

Authors: Susan N Thomas; Efthymia Vokali; Amanda W Lund; Jeffrey A Hubbell; Melody A Swartz
Journal: Biomaterials Date: 2013-10-18 Impact factor: 12.479

6. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.

Authors: Jason Park; Stephen H Wrzesinski; Eric Stern; Michael Look; Jason Criscione; Ragy Ragheb; Steven M Jay; Stacey L Demento; Atu Agawu; Paula Licona Limon; Anthony F Ferrandino; David Gonzalez; Ann Habermann; Richard A Flavell; Tarek M Fahmy
Journal: Nat Mater Date: 2012-07-15 Impact factor: 43.841

7. Infection-mimicking materials to program dendritic cells in situ.

Authors: Omar A Ali; Nathaniel Huebsch; Lan Cao; Glenn Dranoff; David J Mooney
Journal: Nat Mater Date: 2009-01-11 Impact factor: 43.841

7 in total

4 in total

Cancer vaccines: Material breach.

1. In situ regulation of DC subsets and T cells mediates tumor regression in mice.

2. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.

3. Biomaterial-based vaccine induces regression of established intracranial glioma in rats.

4. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

5. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.

6. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.

7. Infection-mimicking materials to program dendritic cells in situ.

Review 1. Hydrogels and scaffolds for immunomodulation.

Review 2. Advances in Biomaterials for Drug Delivery.

Review 3. Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.

Review 4. Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.